There are two known
epigenetic causes of XRCC2 deficiency that appear to increase cancer risk. These are
methylation of the
XRCC2 promoter and epigenetic repression of
XRCC2 by over-expression of
EZH2 protein. The
XRCC2 gene was found to be hypermethylated in the promoter region in 52 of 54 cases of cervical cancer. Promoter hypermethylation reduces gene expression, and thus would reduce the tumor suppressing homologous recombinational repair otherwise supported by
XRCC2. Increased expression of EZH2 leads to epigenetic repression of RAD51 paralogs, including XRCC2, and thus reduces
homologous recombinational repair. This reduction was proposed to be a cause of breast cancer. EZH2 protein is up-regulated in numerous cancers. EZH2 mRNA is up-regulated, on average, 7.5-fold in breast cancer, and between 40% and 75% of breast cancers have over-expressed EZH2 protein. == References ==